Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors
May 08, 2023 08:00 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel...
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
March 30, 2023 16:05 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., March 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel...
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
March 16, 2023 08:00 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic...
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare Conference
March 07, 2023 08:00 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic...
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 01, 2023 16:05 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic...
Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
February 27, 2023 16:05 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic...
Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
February 22, 2023 20:41 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic...
Aprea Therapeutics Announces Proposed Public Offering of Common Stock
February 22, 2023 16:05 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic...
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
February 15, 2023 08:00 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
February 13, 2023 07:00 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer...